1. Microbiology and Infectious Disease

Ribonucleotide reductase, a novel drug target for gonorrhea

  1. Jana Narasimhan  Is a corresponding author
  2. Suzanne Letinski
  3. Stephen P Jung
  4. Aleksey Gerasyuto
  5. Jiashi Wang
  6. Michael Arnold
  7. Guangming Chen
  8. Jean Hedrick
  9. Melissa Dumble
  10. Kanchana Ravichandran
  11. Talya Levitz
  12. Cui Chang
  13. Catherine L Drennan
  14. JoAnne Stubbe  Is a corresponding author
  15. Gary Karp
  16. Arthur Branstrom  Is a corresponding author
  1. PTC Therapeutics, Inc., United States
  2. Bristol Myers Squibb, United States
  3. Schrödinger, Inc., United States
  4. PMV Pharmaceuticals, United States
  5. Massachusetts Institute of Technology, United States
  6. Howard Hughes Medical Institute, Massachusetts Institute of Technology, United States
  7. PTC Therapeutics Inc, United States
https://doi.org/10.7554/eLife.67447
Share this article
Cite this article
  1. Jana Narasimhan
  2. Suzanne Letinski
  3. Stephen P Jung
  4. Aleksey Gerasyuto
  5. Jiashi Wang
  6. Michael Arnold
  7. Guangming Chen
  8. Jean Hedrick
  9. Melissa Dumble
  10. Kanchana Ravichandran
  11. Talya Levitz
  12. Cui Chang
  13. Catherine L Drennan
  14. JoAnne Stubbe
  15. Gary Karp
  16. Arthur Branstrom
(2022)
Ribonucleotide reductase, a novel drug target for gonorrhea
eLife 11:e67447.
https://doi.org/10.7554/eLife.67447
  2. Download BibTeX
  3. Download .RIS

Abstract

Antibiotic resistant Neisseria gonorrhoeae (Ng) are an emerging public health threat due to increasing numbers of multidrug resistant (MDR) organisms. We identified two novel orally active inhibitors, PTC-847 and PTC-672, that exhibit a narrow spectrum of activity against Ng including MDR isolates. By selecting organisms resistant to the novel inhibitors and sequencing their genomes, we identified a new therapeutic target, the class Ia ribonucleotide reductase (RNR). Resistance mutations in Ng map to the N-terminal cone domain of the α subunit, which we show here is involved in forming an inhibited a4b4 state in the presence of the b subunit and allosteric effector dATP. Enzyme assays confirm that PTC-847 and PTC-672 inhibit Ng RNR and reveal that allosteric effector dATP potentiates the inhibitory effect. Oral administration of PTC-672 reduces Ng infection in a mouse model and may have therapeutic potential for treatment of Ng that is resistant to current drugs.

Data availability

All data generated or analyzed during this study are included in the manuscript and supplemental section.

Article and author information

Author details

  1. Jana Narasimhan

    Pharmacology and Biomarkers, PTC Therapeutics, Inc., South Plainfield, United States
    For correspondence
    jnarasimhan@ptcbio.com
    Competing interests
    Jana Narasimhan, was employed by PTC Therapeutics when the work was performed and received salary and compensation during their tenure..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5621-8592

  2. Suzanne Letinski

    Analytical Development and Attribute Sciences, Bristol Myers Squibb, New Brunswick, United States
    Competing interests
    Suzanne Letinski, was employed by PTC Therapeutics when the work was performed and received salary and compensation during their tenure..

  3. Stephen P Jung

    Pharmacology and Biomarkers, PTC Therapeutics, Inc., South Plainfield, United States
    Competing interests
    Stephen P Jung, was employed by PTC Therapeutics when the work was performed and received salary and compensation during their tenure..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9276-175X

  4. Aleksey Gerasyuto

    Medicinal Chemistry, Schrödinger, Inc., New York, United States
    Competing interests
    Aleksey Gerasyuto, was employed by PTC Therapeutics when the work was performed and received salary and compensation during their tenure..

  5. Jiashi Wang

    Medicinal Chemistry, Schrödinger, Inc., New York, United States
    Competing interests
    Jiashi Wang, was employed by PTC Therapeutics when the work was performed and received salary and compensation during their tenure..

  6. Michael Arnold

    Chemistry, PTC Therapeutics, Inc., South Plainfield, United States
    Competing interests
    Michael Arnold, Arnold,were employed by PTC Therapeutics when the work wasperformed and received salary and compensation during their tenure.

  7. Guangming Chen

    Chemistry, PTC Therapeutics, Inc., South Plainfield, United States
    Competing interests
    Guangming Chen, was employed by PTC Therapeutics when the work was performed and received salary and compensation during their tenure..

  8. Jean Hedrick

    Pharmacology and Biomarkers, PTC Therapeutics, Inc., South Plainfield, United States
    Competing interests
    Jean Hedrick, was employed by PTC Therapeutics when the work was performed and received salary and compensation during their tenure..

  9. Melissa Dumble

    Preclinical Development and Translational Science, PMV Pharmaceuticals, Cranbury, United States
    Competing interests
    Melissa Dumble, was employed by PTC Therapeutics when the work was performed and received salary and compensation during their tenure..

  10. Kanchana Ravichandran

    Department of Chemistry, Massachusetts Institute of Technology, Cambridge, United States
    Competing interests
    No competing interests declared.

  11. Talya Levitz

    Department of Biology, Massachusetts Institute of Technology, Cambridge, United States
    Competing interests
    No competing interests declared.

  12. Cui Chang

    Department of Biology, Massachusetts Institute of Technology, Cambridge, United States
    Competing interests
    No competing interests declared.

  13. Catherine L Drennan

    Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5486-2755

  14. JoAnne Stubbe

    Department of Chemistry, Massachusetts Institute of Technology, Cambridge, United States
    For correspondence
    stubbe@mit.edu
    Competing interests
    No competing interests declared.

  15. Gary Karp

    Chemistry, PTC Therapeutics, Inc., South Plainfield, United States
    Competing interests
    Gary Karp, was employed by PTC Therapeutics when the work was performed and received salary and compensation during their tenure..

  16. Arthur Branstrom

    Biology, PTC Therapeutics Inc, South Plainfield, United States
    For correspondence
    abranstrom@ptcbio.com
    Competing interests
    Arthur Branstrom, was employed by PTC Therapeutics when the work was performed and received salary and compensation during their tenure.

Funding

Wellcome Trust (097753)

  • Arthur Branstrom

National Institutes of Health (GM126982)

  • Catherine L Drennan

National Institutes of Health (GM007287)

  • Talya Levitz

National Science Foundation (2017246757)

  • Talya Levitz

National Institutes of Health (GM29595)

  • JoAnne Stubbe

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: Animal studies were done according to procedures reviewed and approved by the Rutgers Institutional Animal Care and Use Committee (IACUC). The IACUC protocol ID used was I12-075-12

Copyright

© 2022, Narasimhan et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,467
    views
  • 244
    downloads
  • 10
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Jana Narasimhan
  2. Suzanne Letinski
  3. Stephen P Jung
  4. Aleksey Gerasyuto
  5. Jiashi Wang
  6. Michael Arnold
  7. Guangming Chen
  8. Jean Hedrick
  9. Melissa Dumble
  10. Kanchana Ravichandran
  11. Talya Levitz
  12. Cui Chang
  13. Catherine L Drennan
  14. JoAnne Stubbe
  15. Gary Karp
  16. Arthur Branstrom
(2022)
Ribonucleotide reductase, a novel drug target for gonorrhea
eLife 11:e67447.
https://doi.org/10.7554/eLife.67447

Share this article

https://doi.org/10.7554/eLife.67447

Categories and tags

Further reading

    1. Medicine
    2. Microbiology and Infectious Disease

    Differences in HIV-1 reservoir size, landscape characteristics, and decay dynamics in acute and chronic treated HIV-1 Clade C infection

    Kavidha Reddy, Guinevere Q Lee ... Thumbi Ndung'u
    Research Article

    Persisting HIV reservoir viruses in resting CD4 T cells and other cellular subsets are a barrier to cure efforts. Early antiretroviral therapy (ART) enables post-treatment viral control in some cases, but mechanisms remain unclear. We hypothesised that ART initiated before peak viremia impacts HIV-1 subtype C reservoirs. We studied 35 women at high risk of infection from Durban, South Africa, identified with hyperacute HIV by twice-weekly HIV-RNA testing. Participants included 11 starting ART at a median of 456 (297–1203) days post-onset of viremia (DPOV) and 24 at 1 (1–3) DPOV. Peripheral blood mononuclear cells (PBMCs) were used to measured total HIV-1 DNA by droplet digital PCR (ddPCR) and sequence viral reservoir genomes by full-length proviral sequencing (FLIP-seq). ART during hyperacute infection blunted peak viremia (p<0.0001), but contemporaneous total HIV-1 DNA did not differ (p=0.104). Over 1 year, a decline of total HIV-1 DNA was observed in early treated persons (p=0.0004), but not late treated. Among 697 viral genome sequences, the proviral genetic landscape differed between untreated, late treated, and early treated groups. Intact genomes after 1 year were higher in untreated (31%) versus late treated (14%) and early treated (0%). Treatment in both late and early infection caused more rapid decay of intact (13% and 51% per month) versus defective (2% and 35%) viral genomes. However, intact genomes persisted 1 year post chronic treatment but were undetectable with early ART. Early ART also reduced phylogenetic diversity of intact genomes and limited cytotoxic T lymphocyte immune escape variants in the reservoir. Overall, ART initiated in hyperacute HIV-1 subtype C infection did not impact reservoir seeding but was associated with rapid intact viral genome decay, reduced genetic complexity, and limited immune escape, which may accelerate reservoir clearance in combination with other interventional strategies.

    1. Immunology and Inflammation
    2. Microbiology and Infectious Disease

    The relationship between gut and nasopharyngeal microbiome composition can predict the severity of COVID-19

    Benita Martin-Castaño, Patricia Diez-Echave ... Julio Galvez
    Research Article

    Coronavirus disease 2019 (COVID-19) is a respiratory illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that displays great variability in clinical phenotype. Many factors have been described to be correlated with its severity, and microbiota could play a key role in the infection, progression, and outcome of the disease. SARS-CoV-2 infection has been associated with nasopharyngeal and gut dysbiosis and higher abundance of opportunistic pathogens. To identify new prognostic markers for the disease, a multicentre prospective observational cohort study was carried out in COVID-19 patients divided into three cohorts based on symptomatology: mild (n = 24), moderate (n = 51), and severe/critical (n = 31). Faecal and nasopharyngeal samples were taken, and the microbiota was analysed. Linear discriminant analysis identified Mycoplasma salivarium, Prevotella dentalis, and Haemophilus parainfluenzae as biomarkers of severe COVID-19 in nasopharyngeal microbiota, while Prevotella bivia and Prevotella timonensis were defined in faecal microbiota. Additionally, a connection between faecal and nasopharyngeal microbiota was identified, with a significant ratio between P. timonensis (faeces) and P. dentalis and M. salivarium (nasopharyngeal) abundances found in critically ill patients. This ratio could serve as a novel prognostic tool for identifying severe COVID-19 cases.

    1. Microbiology and Infectious Disease

    Maintenance of cell wall remodeling and vesicle production are connected in Mycobacterium tuberculosis

    Vivian C Salgueiro-Toledo, Jorge Bertol ... Rafael Prados-Rosales
    Research Article

    Pathogenic and nonpathogenic mycobacteria secrete extracellular vesicles (EVs) under various conditions. EVs produced by Mycobacterium tuberculosis (Mtb) have raised significant interest for their potential in cell communication, nutrient acquisition, and immune evasion. However, the relevance of vesicle secretion during tuberculosis infection remains unknown due to the limited understanding of mycobacterial vesicle biogenesis. We have previously shown that a transposon mutant in the LCP-related gene virR (virRmut) manifested a strong attenuated phenotype during experimental macrophage and murine infections, concomitant to enhanced vesicle release. In this study, we aimed to understand the role of VirR in the vesicle production process in Mtb. We employ genetic, transcriptional, proteomics, ultrastructural, and biochemical methods to investigate the underlying processes explaining the enhanced vesiculogenesis phenomenon observed in the virRmut. Our results establish that VirR is critical to sustain proper cell permeability via regulation of cell envelope remodeling possibly through the interaction with similar cell envelope proteins, which control the link between peptidoglycan and arabinogalactan. These findings advance our understanding of mycobacterial extracellular vesicle biogenesis and suggest that these set of proteins could be attractive targets for therapeutic intervention.